Evidence map›Paper›PMID 36732618›Full record

ArticleGene therapy2025

Antibody-based protection against respiratory syncytial virus in mice and their offspring through vectored immunoprophylaxis.

Amira D Rghei, Jacob G E Yates, Jordyn A Lopes, Xuiaoyan Zhan, Matthew M Guilleman, Yanlong Pei, Laura P van Lieshout, Lisa A Santry, Byram W Bridle, Khalil Karimi and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Amira D RgheiDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Jacob G E YatesDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Jordyn A LopesDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Xuiaoyan ZhanVanderbilt Vaccine Center, Vanderbilt University, Nashville, TN, 37232-0417, USA.
Matthew M GuillemanDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Yanlong PeiDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Laura P van LieshoutDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Lisa A SantryDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Byram W BridleDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Khalil KarimiDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Brad ThompsonAvamab Pharma Inc., Calgary, AB, T2T 2P9, Canada.
Leonardo SustaDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada.
James E CroweVanderbilt Vaccine Center, Vanderbilt University, Nashville, TN, 37232-0417, USA.
Sarah K WoottonDepartment of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada. kwootton@uoguelph.ca.ORCID 0000-0002-5985-2406
University of Guelph · CAVanderbilt University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) causes acute lower respiratory tract infections, with potential lower respiratory tract infections, which can be particularly problematic in infants and the elderly. There are no approved vaccines for RSV. The current standard of care for high-risk individuals is monthly administration of palivizumab, a humanized murine monoclonal antibody (mAb) targeting the RSV fusion protein. Adeno-associated virus (AAV)-mediated expression of mAbs has previously led to sustained expression of therapeutic concentrations of mAbs in several animal models, representing an alternative to repetitive passive administration. Intramuscular (IM) administration of AAV6.2FF expressing RSV antibodies, palivizumab or hRSV90, resulted in high concentrations of human (h)IgG1 mAbs in the serum and at various mucosal surfaces, while intranasal administration limited hIgG expression to the respiratory tract. IM administration of AAV6.2FF-hRSV90 or AAV6.2FF-palivizumab in a murine model provided sterilizing immunity against challenge with RSV A2. Evidence of maternal passive transfer of vectorized hRSV90 was detected in both murine and ovine models, with circulating mAbs providing sterilizing immunity in mouse progeny. Finally, addition of a "kill switch" comprised of LoxP sites flanking the mAb genes resulted in diminished serum hIgG after AAV-DJ-mediated delivery of Cre recombinase to the same muscle group that was originally transduced with the AAV-mAb vector. The ability of this AAV-mAb system to mediate robust, sustained mAb expression for maternal transfer to progeny in murine and ovine models emphasizes the potential of this platform for use as an alternative prophylactic vaccine for protection against neonatal infections, particularly in high-risk infants.

Indexed as

Antibodies, MonoclonalAntibodies, ViralRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsAnimalsDependovirusFemaleGenetic VectorsHumansImmunization, PassiveMicePalivizumabSheepAntibodies, MonoclonalAntibodies, ViralPalivizumab

Identifiers

PMID36732618
OpenAlexW4319036852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.